Get the Stockscreener App
8.02
4.75%
-0.40
After Hours:
7.86
-0.16
-2.00%
Corbus Pharmaceuticals Holdings Inc stock is traded at $8.02, with a volume of 330.95K.
It is down -4.75% in the last 24 hours and up +8.53% over the past month.
Corbus Pharmaceuticals Holdings Inc is a precision oncology company with a diversified portfolio and is committed to helping people defeat serious illness by bringing scientific approaches to well-understood biological pathways. The company's development pipeline includes; CRB-701, a next-generation antibody-drug conjugate (ADC) that targets the expression of Nectin-4 on cancer cells to release a cytotoxic payload, CRB-601, an anti-integrin monoclonal antibody that blocks the activation of TGF expressed on cancer cells, and CRB-913 a second-generation peripherally restricted CB1 receptor inverse agonist designed to treat obesity.
See More
Previous Close:
$8.42
Open:
$8.39
24h Volume:
330.95K
Relative Volume:
1.23
Market Cap:
$140.78M
Revenue:
$1.54M
Net Income/Loss:
$-38.70M
P/E Ratio:
-1.7173
EPS:
-4.67
Net Cash Flow:
$-36.86M
1W Performance:
-2.79%
1M Performance:
+8.53%
6M Performance:
-18.66%
1Y Performance:
+17.25%
1-Day Range:
$7.68
$8.39
1-Week Range:
$7.68
$8.72
52-Week Range:
$4.64
$20.56
Corbus Pharmaceuticals Holdings Inc Stock (CRBP) Company Profile
Name
Corbus Pharmaceuticals Holdings Inc
Sector
Industry
Phone
617-963-0103
Address
500 RIVER RIDGE DRIVE, NORWOOD, MA
Compare CRBP vs VRTX, REGN, ARGX, ALNY, ONC
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
CRBP
Corbus Pharmaceuticals Holdings Inc
|
8.02 | 147.80M | 1.54M | -38.70M | -36.86M | -4.67 |
|
VRTX
Vertex Pharmaceuticals Inc
|
460.82 | 121.40B | 12.07B | 3.95B | 3.19B | 15.33 |
|
REGN
Regeneron Pharmaceuticals Inc
|
764.93 | 83.25B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
728.11 | 46.39B | 4.16B | 1.29B | 734.26M | 19.59 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
320.51 | 43.41B | 3.71B | 313.75M | 465.38M | 2.2571 |
|
ONC
Beone Medicines Ltd Adr
|
292.94 | 33.09B | 5.36B | 287.73M | 924.18M | 2.5229 |
Corbus Pharmaceuticals Holdings Inc Stock (CRBP) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jul-30-25 | Resumed | B. Riley Securities | Buy |
| Feb-28-25 | Initiated | William Blair | Outperform |
| Dec-02-24 | Initiated | Piper Sandler | Overweight |
| Jul-30-24 | Initiated | Wedbush | Outperform |
| Jul-22-24 | Resumed | H.C. Wainwright | Buy |
| Jun-26-24 | Initiated | B. Riley Securities | Buy |
| Jun-03-24 | Reiterated | Oppenheimer | Outperform |
| May-13-24 | Initiated | RBC Capital Mkts | Outperform |
| Mar-06-24 | Upgrade | Jefferies | Hold → Buy |
| Sep-08-20 | Downgrade | BTIG Research | Buy → Neutral |
| Sep-08-20 | Downgrade | Jefferies | Buy → Hold |
| Sep-08-20 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| Sep-08-20 | Downgrade | ROTH Capital | Buy → Neutral |
| Jul-07-20 | Initiated | ROTH Capital | Buy |
| Jun-17-20 | Initiated | BTIG Research | Buy |
| Mar-26-20 | Initiated | Nomura | Buy |
| Apr-05-19 | Initiated | Jefferies | Buy |
| Mar-20-19 | Initiated | Oppenheimer | Outperform |
| Jan-11-19 | Reiterated | Cantor Fitzgerald | Overweight |
| Dec-26-18 | Initiated | H.C. Wainwright | Buy |
| Dec-07-18 | Initiated | RBC Capital Mkts | Outperform |
| Oct-24-18 | Initiated | B. Riley FBR | Buy |
| Jan-19-18 | Initiated | Raymond James | Outperform |
| Dec-14-17 | Reiterated | Cantor Fitzgerald | Overweight |
| Nov-08-17 | Reiterated | Noble Financial | Buy |
| Sep-29-17 | Resumed | Noble Financial | Buy |
| Mar-30-17 | Reiterated | Cantor Fitzgerald | Overweight |
| Nov-15-16 | Reiterated | JMP Securities | Mkt Outperform |
| Nov-11-16 | Reiterated | Noble Financial | Buy |
View All
Corbus Pharmaceuticals Holdings Inc Stock (CRBP) Latest News
Buyout Rumor: How is Corbus Pharmaceuticals Holdings Inc managing supply chain issuesJuly 2025 Action & Real-Time Sentiment Analysis - baoquankhu1.vn
Corbus Pharmaceuticals Holdings Inc. stock underperforms Wednesday when compared to competitors despite daily gains - MarketWatch
Corbus (NASDAQ: CRBP) CMO offloads shares in tax-related RSU sale - Stock Titan
Corbus Pharmaceuticals Holdings Inc. stock outperforms competitors despite losses on the day - MarketWatch
Corbus Pharmaceuticals (CRBP) to Release Quarterly Earnings on Tuesday - MarketBeat
Insider sale notice — CRBP (NASDAQ: CRBP) lists 12,500 RSUs - Stock Titan
Aug Movers: Can Corbus Pharmaceuticals Holdings Inc maintain its current growth rateJuly 2025 Action & AI Powered Market Trend Analysis - baoquankhu1.vn
How Corbus Pharmaceuticals Holdings Inc. (CRBP) Affects Rotational Strategy Timing - Stock Traders Daily
Fund Flows: Can Corbus Pharmaceuticals Holdings Inc maintain its current growth rate2025 Buyback Activity & Fast Momentum Stock Entry Tips - baoquankhu1.vn
CRBP Should I Buy - Intellectia AI
Corbus Pharmaceuticals Holdings Inc. stock outperforms competitors on strong trading day - MarketWatch
Corbus Pharmaceuticals Holdings, Inc. advances CRB-701 for Nectin-4 solid tumors in early-stage development - Traders Union
Corbus Pharmaceuticals Touts “Catalyst-Rich” 2026 With CRB-701 and CRB-913 Data Readouts Ahead - MarketBeat
Corbus Highlights Diversified Oncology and Metabolic Pipeline Outlook - TipRanks
EDGAR Filing Documents for 0001193125-26-068566 - SEC.gov
Corbus updates corporate presentation, details 2026 clinical and financial milestones - TradingView
Corbus Pharmaceuticals (CRBP) highlights oncology and obesity pipeline progress - Stock Titan
CRBP News Today | Why did Corbus Pharmaceuticals stock go up today? - MarketBeat
Chart Watch: How is Corbus Pharmaceuticals Holdings Inc managing supply chain issuesProduct Launch & Safe Swing Trade Setups - baoquankhu1.vn
Corbus Pharmaceuticals (NASDAQ:CRBP) Stock Rating Upgraded by Jefferies Financial Group - Defense World
Corbus (CRBP) CEO Yuval Cohen sells shares in Rule 10b5-1 tax-cover transaction - Stock Titan
(CRBP) and the Role of Price-Sensitive Allocations - Stock Traders Daily
Working capital per share of Corbus Pharmaceuticals Holdings Inc – LSE:0SZI - TradingView
Corbus Pharmaceuticals Holdings, Inc. (NASDAQ:CRBP) Receives Average Recommendation of "Moderate Buy" from Analysts - MarketBeat
[144] Corbus Pharmaceuticals Holdings, Inc. SEC Filing - Stock Titan
Decliners Report: What is Corbus Pharmaceuticals Holdings Incs revenue forecastJuly 2025 Patterns & Low Drawdown Trading Techniques - baoquankhu1.vn
Corbus Pharmaceuticals to Present at the 36th Annual Oppenheimer Healthcare Life Sciences Conference - Bitget
Corbus Pharmaceuticals to Present at 36th Annual Oppenheimer Healthcare Life Sciences Conference - Quiver Quantitative
Can Corbus Pharmaceuticals Holdings Inc. maintain its current growth rateQuarterly Earnings Summary & AI Driven Stock Price Forecasts - mfd.ru
Stock Recap: What is the cash position of Corbus Pharmaceuticals Holdings IncQuarterly Profit Report & Verified Momentum Stock Alerts - baoquankhu1.vn
Published on: 2026-02-11 16:50:32 - mfd.ru
Should I hold or sell Corbus Pharmaceuticals Holdings Inc. stock in 2025July 2025 Sentiment & Detailed Earnings Play Alerts - mfd.ru
Corbus Pharmaceuticals announces retirement of board member Holmer - MSN
Published on: 2026-02-08 12:15:37 - baoquankhu1.vn
Responsive Playbooks and the CRBP Inflection - Stock Traders Daily
Corbus Pharmaceuticals: Maintaining 'Hold' As Summer 2026 Obesity Data Catalyst Looms - Seeking Alpha
Forecast Cut: What dividend growth rate does Corbus Pharmaceuticals Holdings Inc offerJuly 2025 Intraday Action & Weekly Setup with ROI Potential - baoquankhu1.vn
Corbus Pharmaceuticals (CRBP) Stock Price, News & Analysis - MarketBeat
Dominic Smethurst Sells 3,285 Shares of Corbus Pharmaceuticals (NASDAQ:CRBP) Stock - MarketBeat
Corbus Pharmaceuticals (NASDAQ:CRBP) COO Sells $19,537.35 in Stock - MarketBeat
Corbus Pharmaceuticals Completes $75 Million Public Offering - MSN
Corbus Pharmaceuticals Holdings Inc. Stock Underperforms Tuesday When Compared To Competitors Despite Daily Gains - 富途牛牛
While institutions invested in Corbus Pharmaceuticals Holdings, Inc. (NASDAQ:CRBP) benefited from last week's 12% gain, individual investors stood to gain the most - simplywall.st
Understanding the Setup: (CRBP) and Scalable Risk - Stock Traders Daily
12 Health Care Stocks Moving In Monday's After-Market Session - Benzinga
Corbus Pharmaceuticals Holdings, Inc. (NASDAQ:CRBP) Receives Consensus Rating of "Moderate Buy" from Analysts - MarketBeat
Aberdeen Group plc Expands Holdings in Corbus Pharmaceuticals Ho - GuruFocus
Can Corbus Pharmaceuticals Holdings Inc. stock sustain institutional interestLong Setup & Daily Price Action Insights - bollywoodhelpline.com
Revenue Check: How is Corbus Pharmaceuticals Holdings Inc managing supply chain issues2025 Geopolitical Influence & Accurate Intraday Trading Signals - baoquankhu1.vn
CRBP: CRB-701 and CRB-913 advance with strong data, regulatory clarity, and funding into 2028 - TradingView
Corbus Pharmaceuticals surges on CRB-913 trial success - Intellectia AI
Corbus Pharmaceuticals Holdings Inc Stock (CRBP) Financials Data
Revenue
Net Income
Cash Flow
EPS
3.69%
0.68%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):